Population Health Partners
VC Fund
San Francisco, United States
Population Health Partners is an investment company focused on innovative therapeutics with the potential to transform health outcomes for populations.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Population Health Partners invests in
Stages Population Health Partners invests in
Countries Population Health Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Clive Meanwell
|
|||
Farah Champsi
|
|||
Greg Williams
|
|||
Tom Denwood
|
|||
Whit Bernard
|
Investment Focus
Industry
- Biotechnology 5 (45%)
- Health Care 3 (27%)
- Life Science 3 (27%)
- Therapeutics 3 (27%)
- Pharmaceutical 3 (27%)
Stage
- Series A 3 (27%)
- Seed 1 (9%)
- Series B 1 (9%)
- Series C 1 (9%)
- Series F 1 (9%)
Country
- United States 6 (55%)
- The Netherlands 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Clive Meanwell
Executive Chairman & Co-Founder
|
Executive Chairman & Co-Founder | Total investments: 4 | Find email | |
|
Farah Champsi
Partner
|
Partner | Total investments: 12 | Find email | |
|
Greg Williams
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
|
Tom Denwood
Chief Digital Officer
|
Chief Digital Officer | Total investments: 0 | Find email | |
|
Whit Bernard
Managing Partner
|
Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Corsera Health
|
Corsera Health develops preventive RNA interference medicines focused on reducing cardiovascular disease risk before long-term damage occurs. The company’s approach targets two biological drivers of cardiovascular disease by silencing PCSK9 to lower LDL cholesterol and AGT to reduce blood pressure. Its RNAi platform works by decreasing theproduction of these proteins at the gene expression level, aiming to alter disease progression through early intervention. Corsera Health designs its medicines for once-yearly administration to support long-term adherence and simplify preventive care. The company’s development strategy emphasizes broad population use and accessibility through scalable manufacturing and pricing structures suited for preventive treatment. | $80M / Series A / Jan 07, 2026 | |
Metsera
|
Metsera operates as a clinical-stage biopharmaceutical company. | Seed / Apr 18, 2024 | |
Areteia Therapeutics
|
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments. | $75M / Series A / Feb 13, 2024 | |
|
Areteia Therapeutics
|
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments. | $75M / Series A / Feb 13, 2024 | |
|
Areteia Therapeutics
|
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments. | $350M / Series A / Jul 12, 2022 | |
|
Areteia Therapeutics
|
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments. | $350M / Series A / Jul 12, 2022 | |
Saama
|
Saama is the number one AI-powered clinical analytics cloud platform company, unleashing wisdom from data to deliver better business outcomes for the life sciences industry. Saama’s unified, AI-driven clinical data analytics platform seamlessly integrates, curates, and animates unlimited sources of structured, unstructured, and real-world data todeliver actionable insights across all therapeutic areas. The award-winning platform gives unprecedented real-time visibility into clinical data, enabling sponsors to file New Drug Applications (NDAs) more efficiently to bring drugs to market faster and at lower costs. For more information, visit http://www.saama.com. | Private Equity / Oct 20, 2021 | |
Fractyl Health
|
Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease. | $100M / Series F / Jun 16, 2021 | |
Invivyd
|
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patientsand clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with thirdparty contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. | $336M / Series C / Apr 19, 2021 | |
New Amsterdam Pharma
|
NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. | $194.4M / Series A / Jan 14, 2021 | |
| See all 11 investments → | |||
Co-Investors
Google Ventures
6 deals together
ARCH Venture Partners
5 deals together
Maverick Capital
5 deals together
Access Biotechnology
4 deals together
Bain Capital Life Sciences
4 deals together
Sanofi
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Population Health Partners invest in?
Population Health Partners invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Population Health Partners?
Public channels for Population Health Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Population Health Partners?
The team at Population Health Partners includes Clive Meanwell (Executive Chairman & Co-Founder), Farah Champsi (Partner) and Greg Williams (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
